These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36276487)

  • 1. Effect of the PARP inhibitor veliparib on germ cell tumor cell lines.
    Schmidtova S; Udvorkova N; Cierna Z; Horak S; Kalavska K; Chovanec M; Rojikova L; Vulevova M; Kucerova L; Mego M
    Oncol Lett; 2022 Nov; 24(5):392. PubMed ID: 36276487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
    Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.
    Schmidtova S; Kalavska K; Liskova V; Plava J; Miklikova S; Kucerova L; Matuskova M; Rojikova L; Cierna Z; Rogozea A; Konig H; Albany C; Mego M; Chovanec M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
    Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells.
    Schmidtova S; Kalavska K; Gercakova K; Cierna Z; Miklikova S; Smolkova B; Buocikova V; Miskovska V; Durinikova E; Burikova M; Chovanec M; Matuskova M; Mego M; Kucerova L
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31443351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
    Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D
    Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
    Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
    PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
    Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
    Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
    J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours.
    Bremmer F; Schallenberg S; Jarry H; Küffer S; Kaulfuss S; Burfeind P; Strauß A; Thelen P; Radzun HJ; Ströbel P; Honecker F; Behnes CL
    Oncotarget; 2015 Oct; 6(32):33426-37. PubMed ID: 26451610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.
    Port M; Glaesener S; Ruf C; Riecke A; Bokemeyer C; Meineke V; Honecker F; Abend M
    Mol Cancer; 2011 May; 10():52. PubMed ID: 21575166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.
    Fichtner A; Bohnenberger H; Elakad O; Richter A; Lenz C; Oing C; Ströbel P; Kueffer S; Nettersheim D; Bremmer F
    World J Urol; 2022 Feb; 40(2):373-383. PubMed ID: 35084545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomics reveals
    Stolzenburg LR; Ainsworth B; Riley-Gillis B; Pakozdi T; Ammar A; Ellis PA; Wilsbacher JL; Ramathal CY
    Oncotarget; 2022; 13():1-12. PubMed ID: 35018214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
    Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
    ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.
    Mayer F; Mueller S; Malenke E; Kuczyk M; Hartmann JT; Bokemeyer C
    Invest New Drugs; 2005 Jun; 23(3):205-11. PubMed ID: 15868376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
    Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
    Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
    Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
    Patel AG; De Lorenzo SB; Flatten KS; Poirier GG; Kaufmann SH
    Clin Cancer Res; 2012 Mar; 18(6):1655-62. PubMed ID: 22291137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma.
    Wang J; Xing W; Lin Y; Uskenbayeva N; Yan H; Xu Y; Fang L
    J Clin Lab Anal; 2022 May; 36(5):e24435. PubMed ID: 35421273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of
    Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.